PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
S. Loibl, G. von Minckwitz, A. Schneeweiss, S. Paepke +21 more

